Vicapsys Life Sciences, Inc. (OTCMKTS:VICP – Get Free Report) was down 36.1% during mid-day trading on Wednesday . The stock traded as low as $0.62 and last traded at $0.62. Approximately 107 shares were traded during trading, a decline of 40% from the average daily volume of 179 shares. The stock had previously closed at $0.97.
Vicapsys Life Sciences Stock Performance
The company’s 50-day simple moving average is $1.75 and its 200-day simple moving average is $2.20.
About Vicapsys Life Sciences
Vicapsys Life Sciences, Inc focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers.
Read More
- Five stocks we like better than Vicapsys Life Sciences
- How to Evaluate a Stock Before Buying
- Comprehensive Analysis of PayPal Stock
- 3 Stocks to Consider Buying in October
- Intuitive Surgical Stock Can Trend Much Higher This Year
- Investing in Commodities: What Are They? How to Invest in Them
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Vicapsys Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vicapsys Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.